Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

被引：0
|
作者：
Rubinstein, A. [1 ,2 ]
Wasserman, R. L. [3 ]
Melamed, I. [4 ]
Stein, M. [5 ]
McCoy, B. [6 ]
Engl, W. [6 ]
Leibl, H. [6 ]
Gelmont, D. [7 ]
Schiff, R. I. [7 ]
Grossman, W. J. [7 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY 10467 USA
[2] Montefiore Hosp, Bronx, NY USA
[3] DallasAllergyImmunol, Dallas, TX USA
[4] IMMUNOe, Centennial, CO USA
[5] Allergy Associates Palm Beaches, N Palm Beach, FL USA
[6] Baxter BioSci, Vienna, Austria
[7] Baxter BioSci, Westlake Village, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2011年 / 127卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2010.12.848
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：AB213 / AB213
页数：1
相关论文
共 50 条
  • [1] Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients
    Gelmont, D.
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Rubinstein, A.
    McCoy, B.
    Engl, W.
    Leibl, H.
    Schiff, R. I.
    Grossman, W. J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB15 - AB15
  • [2] Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)
    Stein, M.
    Wasserman, R. L.
    Melamed, I.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB14 - AB14
  • [3] PHARMACOKINETICS (PK) OF HUMAN IMMUNOGLOBULIN 10% (IGG) ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASE (PIDD)
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Rubinstein, A.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Schiff, R. I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A94 - A94
  • [4] Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency (PI)
    Stein, Mark
    Wasserman, Richard
    Melamed, Isaac
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    Gelmont, David
    Schiff, Richard
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 364 - 365
  • [5] PHARMACOKINETICS OF HUMAN IMMUNOGLOBULIN G, 10%, ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY): SUBSET OF PATIENTS WITH PRIMARY IMMUNODEFICIENCY
    Stein, M.
    Wasserman, R. L.
    Melamed, I.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 156 - 157
  • [6] PHARMACOKINETICS OF HUMAN IMMUNOGLOBULIN G, 10%, ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Rubinstein, A.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 136 - 136
  • [7] PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SINGLE SUBCUTANEOUS (SC) DOSES OF TOCILIZUMAB (TCZ) ADMINISTERED WITH AND WITHOUT rHuPH20, A RECOMBINANT HUMAN HYALURONIDASE, IN HEALTHY VOLUNTEERS
    Morcos, P. N.
    McIntyre, C.
    Bittner, B.
    Rowell, L.
    Hussain, Z.
    Zhang, X.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S57 - S57
  • [8] The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients with Advanced Illness
    Thomas, Jay R.
    Wallace, Mark S.
    Yocum, Richard C.
    Vaughn, Daniel E.
    Haller, Michael F.
    Flament, Jocelyne
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2009, 38 (05) : 663 - 672
  • [9] Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers
    Harb, George
    Lebel, Francois
    Battikha, Jean
    Thackara, Jeffrey W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (02) : 279 - 288
  • [10] Effects of Recombinant Human Hyaluronidase (rHuPH20) on Subcutaneous Administration of 10% and 20% IgG in Yucatan Mini Pigs
    Bee, W. H.
    Nekoroski, T.
    Zhang, L.
    Kang, D.
    Teschner, W.
    Schwarz, H. P.
    Muchitsch, E. M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB139 - AB139
12345